Based on this, our study here characterized that atractylenolide I is a safe and effective drug for the treatment of AOM/DSS-induced caCRC, and its mechanism is mainly to inhibit the activation of Drp1 and NLRP3 inflammasomes. This evidence concerns the gene DNM1L and infectious otitis media.